lifestyle.briefmobile.com

Author: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

May 12, 2026
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

May 10, 2026
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

May 5, 2026
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

May 4, 2026
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

May 4, 2026
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

April 29, 2026
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

April 29, 2026
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

April 29, 2026
Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

April 29, 2026
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

April 28, 2026